SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant selling pressure, with community sentiment deeply polarized between investors viewing the recent decline as a forced liquidation event and those identifying a generational buying opportunity. The ongoing debate centers on the sustainability of Saylor's BTC-accumulation strategy, the burden of rising dividend obligations from preferred securities, and the stock's weakening correlation with Bitcoin price action.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is experiencing significant volatility driven by index reconstitution selling and a specific pause in a Wyoming data center project, causing investors to weigh these temporary headwinds against the company's long-term role in AI power infrastructure. The community remains largely polarized, with many using the sharp price pullback as a high-conviction buying opportunity while others express caution regarding valuation sustainability and recent technical breakdowns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened activity and investor interest driven by persistent buyout rumors and significant trading volume, as the community debates whether the stock is undervalued given its product portfolio and cash position. Shareholders remain deeply divided, with some betting on a potential hostile takeover or acquisition while others express frustration over leadership and the stock's failure to maintain momentum.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors engage in a heated debate over whether the stock will graduate to the Russell 1000 index, with many bullish traders betting on forced institutional buying while skeptics warn of potential short-driven volatility. Community conversation is dominated by high-conviction longs anticipating a massive squeeze and long-term breakthroughs in oncology, countering persistent short-seller pressure.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing high volatility as traders react to conflicting reports regarding the status of the Strait of Hormuz and ongoing U.S.-Iran negotiations. The community is deeply divided between those betting on a rapid supply-driven price crash following potential de-escalation and those anticipating further spikes due to persistent geopolitical instability and tight energy inventories.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor reports of a potential Japanese delegation visiting Greenland to evaluate rare earth opportunities, fueling hopes for strategic partnerships that could bypass Chinese supply chains. While the community remains divided on the pace of project development and communication, many shareholders are highlighting the stock's long-term potential as a critical component of Western defense and industrial supply independence.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors digest the announcement of a late July FDA Advisory Committee meeting for Deramiocel, alongside new five-year data highlighting the therapy's durability. While some community members express concern over the potential for added volatility or delays, the majority of the discussion remains bullish, focusing on the FDA's shift toward increased transparency and the company's strong clinical evidence as catalysts for an imminent approval.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail investors debate the stock's future amid a tug-of-war between strong fundamental developments in AI-integrated telecom infrastructure and frustrating, stagnant short-term price action. Community sentiment is deeply polarized, with many retail traders expressing fatigue over daily sell-offs while others point to significant insider buying, positive analyst revisions, and expanding partnerships with tech giants as reasons to hold for a long-term turnaround.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as retail investors weigh the recent loss of a key Medicare reimbursement court case against the company's strong revenue growth and upcoming clinical milestones. The community is actively debating whether the stock is undervalued or if potential institutional sell-offs and the impact of competing therapies will continue to weigh on the share price in the near term.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors focus on upcoming clinical catalysts, including an FDA advisory committee meeting for its mRNA flu vaccine and a specialized investor event showcasing its AI-driven oncology pipeline. The community is actively discussing the stock's potential for a trend reversal, with some noting recent institutional accumulation while others debate the long-term impact of regulatory headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Woodward (WWD) Surges 4.7%: Is This an Indication of Further Gains?

Woodward (WWD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Astronics Announces 20% Class B Stock Distribution

Astronics Corporation (Nasdaq: ATRO), a leading supplier of advanced technologies and products to the global aerospace, defense, and other mission critical industries, today announced a 20% stock distribution of Class B Stock to holders of both Common and Class B Stock. Shareholders will receive...

Astronics Corporation Receives Production Order for TS-4549/T Radio Test Sets Program

Astronics Corporation (Nasdaq: ATRO), a leading provider of advanced technologies for global aerospace, defense and other mission critical industries, announced today that the U.S. Army has issued a purchase order to Astronics Test Systems for the TS-4549/T Radio Test Sets Program. The order...

ATRO vs. AIR: Which Aerospace Services Stock Offers Better Potential?

Astronics vs. AAR: cabin-tech upgrades and expanded A320 repair services keep this aerospace services matchup tight as travel and MRO demand rebound.

What to Know About This Fund's $59 Million Astronics Bet Amid a 170% One-Year Stock Surge

Key PointsPertento Partners acquired 815,333 shares of Astronics last quarter; the estimated trade size was $59.07 million based on quarterly average prices...

Is Astronics (ATRO) Stock Outpacing Its Aerospace Peers This Year?

Here is how Astronics Corporation (ATRO) and Howmet (HWM) have performed compared to their sector so far this year.

Astronics (ATRO) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Astronics Corporation (ATRO) Q1 Earnings and Revenues Top Estimates

Astronics (ATRO) delivered earnings and revenue surprises of +7.27% and +3.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Astronics Corporation Reports 12% Sales Growth for First Quarter 2026

Astronics Corporation (Nasdaq: ATRO) (Astronics or the Company), a leading supplier of advanced technologies and products to the global aerospace, defense, and other mission critical industries...

ATRO Outperforms Industry in a Month: Should You Buy the Stock?

ATRO gains on strong aerospace innovation, rising earnings estimates and discounted valuation, positioning the stock for long-term growth.

Astronics Corp. engages in the provision of electrical power generation and distribution systems. The firm includes motion systems, lighting and safety systems, avionics products, aircraft structures, systems certification, and automated test systems. It operates through the Aerospace and Test Systems segments. The Aerospace segment designs and manufactures products for the global aerospace industry. The Test Systems segment designs, develops, manufactures and maintains communications and weapons test systems and training and simulation devices for military applications. The company was founded in 1968 and is headquartered in East Aurora, NY.

Astronics Corp.

Astronics Corp Stock Rises After-Hours As Q4 Profit Tops Estimates, Retail’s Yet To Take Notice

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.53	--	--	N/A
Q1 '26	$0.56	$0.47	-15.93%	MISSED
Q4 '25	$0.60	$0.75	25.00%	BEAT
Q3 '25	$0.42	$0.49	16.67%	BEAT
Q2 '25	$0.33	$0.04	-87.88%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATROAstronics Corp.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest ATRO News